Tirzepatide beats semaglutide for heart protection in 70,672 non-diabetic adults with obesity

Key Findings

💊 Pharmacist-led GLP-1 management doubles blood sugar improvements

• Among 128 patients with type 2 diabetes, those managed by clinical pharmacists had nearly double the reduction in HbA1c (19.9% vs 10.2%)

• Pharmacist-managed patients also had more frequent dose adjustments and better insulin de-escalation

• The benefit held despite both groups having similar baseline characteristics and medication access

🏥 GLP-1 drugs linked to 43% lower death risk after liver transplant

• Among 1,082 liver transplant recipients, those prescribed GLP-1 drugs within a month of surgery had 43% lower all-cause mortality over 2+ years

• Users also had 39% fewer hospitalizations and significantly reduced heart failure, kidney failure, and respiratory complications

• No differences in graft rejection or failure were observed, suggesting the drugs don't compromise transplant success

😴 GLP-1 users 23% more likely to develop excessive sleepiness

• Analysis of 237,986 patients found GLP-1 drug users had increased risk of hypersomnolence at both 1 year (21% higher) and 5 years (23% higher)

• The absolute risk increase was small—about 0.4% at 1 year and 0.7% at 5 years

• Iron deficiency was also more common among long-term users, which could contribute to fatigue

🧠 Dual hormone approach shows promise for advanced diabetes

• In diabetic mice with severe, uncontrolled blood sugar, a new dual GLP-1/GLP-2 drug (PG-102) achieved better glucose control than semaglutide or tirzepatide while preserving body weight

• Phase 1 trial in 24 adults showed the drug was well-tolerated with mostly mild gastrointestinal side effects

• The dual approach may uncouple blood sugar benefits from weight loss—potentially useful when weight loss isn't desired

💪 GLP-1 drugs cause substantial muscle loss alongside fat loss

• Meta-analysis of 15,782 participants found 25-39% of total weight lost with GLP-1 drugs was lean muscle mass, not just fat

• Semaglutide users lost 35% of weight as muscle, while tirzepatide users lost 25%—both similar to lifestyle interventions alone

• Only resistance training combined with lifestyle changes preserved muscle better (18% of weight loss vs 26-35%)

🔬 Scientists discover GLP-1 receptors work through tiny cellular antennas

• Researchers found GLP-1 receptors are concentrated in primary cilia—tiny antenna-like structures on pancreatic beta cells

• When these cellular antennas were disrupted, insulin-producing cells couldn't properly respond to GLP-1 drugs

• The discovery reveals a previously unknown mechanism for how these blockbuster medications actually work at the cellular level